According to MannKind Corporation (MNKD) most recent 13F filing, the company has 15 new institutional holders - accounting for 3.85 million shares of its common stock.
MannKind Corporation (NASDAQ:MNKD) was down -0.93% (-$0.03) to $3.21 and showed a volume of 2.57 mln shares.
October 24 investment analysts at HC Wainwright reiterated a "Buy" rating on the company. For the current quarter Mannkind Corporation (NASDAQ:MNKD) has high EPS estimates of $-0.13 in contradiction of low EPS estimates of $-0.29. Of those analysts, 1 rate stock as a Strong Buy, 1 rate it as Hold, and just no analyst rates it as a Moderate Sell.
MannKind Corporation (NASDAQ:MNKD) last announced its earnings results on Tuesday, November 7th.
North Korean Soldier Is Shot While Defecting Across DMZ, South Says
Although there have been a handful of defections across the DMZ in recent years, escapes through the tense Joint Security Area are rare.
On the other hand Mannkind Corporation (NASDAQ:MNKD) has Relative Strength Index (RSI 14) of 45.42 along with Average True Range (ATR 14) of 0.56. The firm has "Buy" rating by Maxim Group given on Friday, September 1. The stock has a market cap of $371.04 million, a PE ratio of 5.98 and a beta of 3.10. Previously Mannkind Corporation (NASDAQ:MNKD) reported $-0.31 earnings per share (EPS) for the quarter, missing the consensus estimate of $-0.2 by $-0.11 with surprise factor of -55%. It has ranged in price between $3.1-$3.28 after having started the session at $3.26 as compared to the previous trading day's close of $3.24. The business had revenue of $2.16 million during the quarter, compared to analyst estimates of $2.75 million. The operating margin is 0 percent and the net profit margin stand at 0 percent. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. KCG Holdings Inc. increased its stake in MannKind Corporation by 268.0% during the 1st quarter. Bank of New York Mellon Corp now owns 108,380 shares of the biopharmaceutical company's stock worth $236,000 after buying an additional 25,125 shares during the period.
The most recent non open market insider trade was completed by ALINAYA ROSABEL REALICA on 08/28/2017, and was a disposition of 243 shares with a final price of $1.55. Wells Fargo & Company MN now owns 89,951 shares of the biopharmaceutical company's stock worth $196,000 after acquiring an additional 30,589 shares in the last quarter. There were 23 sold out positions, amounting to 1.99 million shares. HC Wainwright assumed coverage on MannKind Corporation in a report on Tuesday, October 10th.
WARNING: This article was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of US & global copyright legislation.
MannKind Corporation (MNKD) closed 59.6% above its 200-day moving average and is 0.14% above another chart threshold, its 50-day moving average. The Firm is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Company's product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.
- Milton Santa Claus Parade celebrates 150 years of Christmas Sunday
- Dubai Airshow 2017: Boeing forecasts $730bn Middle East aviation market
- Airport prepares for massive crowds for Thanksgiving weekend
- The Delta Air Lines Inc. (DAL) Lifted to Buy at Vetr Inc
- Head of Public Safety Office denies involvement in altering State Police reports
- CVS Health Corporation (CVS) Earns "Hold" Rating from Robert W. Baird
- Banco Bilbao Viscaya Argentaria SA (BBVA) Is It Worthy for Investors?
- RSI Alert - Ballard Power Systems Inc. (NASDAQ: BLDP)
- EPS Forecast Revision Scan: Altria Group, Inc. (MO)
- Diego Maradona est triste pour l'Italie